Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2017 1
2018 1
2020 2
2021 1
2022 1
2023 2
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Ebola vaccine R&D: Filling the knowledge gaps.
Medaglini D, Harandi AM, Ottenhoff TH, Siegrist CA; VSV-Ebovac Consortium. Medaglini D, et al. Sci Transl Med. 2015 Dec 9;7(317):317ps24. doi: 10.1126/scitranslmed.aad3106. Sci Transl Med. 2015. PMID: 26659569 Free PMC article. Review.
Global blood miRNA profiling unravels early signatures of immunogenicity of Ebola vaccine rVSVΔG-ZEBOV-GP.
Vianello E, Persson J, Andersson B, van Veen S, Dias TL, Santoro F, Östensson M, Obudulu O, Agbajogu C, Torkzadeh S; VSV-EBOVAC; VSV-EBOPLUS Consortia; Nakaya HI, Medaglini D, Siegrist CA, Ottenhoff THM, Harandi AM. Vianello E, et al. iScience. 2023 Nov 23;26(12):108574. doi: 10.1016/j.isci.2023.108574. eCollection 2023 Dec 15. iScience. 2023. PMID: 38162033 Free PMC article.
Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability.
Huttner A, Agnandji ST, Engler O, Hooper JW, Kwilas S, Ricks K, Clements TL, Jonsdottir HR, Nakka SS, Rothenberger S, Kremsner P, Züst R, Medaglini D, Ottenhoff T, Harandi AM, Siegrist CA; VEBCON; VSV-EBOVAC; VSV-EBOPLUS Consortia. Huttner A, et al. Clin Microbiol Infect. 2023 Dec;29(12):1587-1594. doi: 10.1016/j.cmi.2023.08.026. Epub 2023 Sep 3. Clin Microbiol Infect. 2023. PMID: 37661067 Free article.
Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study.
Vianello E, Gonzalez-Dias P, van Veen S, Engele CG, Quinten E, Monath TP, Medaglini D; VSV-EBOVAC Consortium; VSV-EBOPLUS Consortium; Santoro F, Huttner A, Dubey S, Eichberg M, Ndungu FM, Kremsner PG, Essone PN, Agnandji ST, Siegrist CA, Nakaya HI, Ottenhoff THM, Haks MC. Vianello E, et al. Lancet Microbe. 2022 Feb;3(2):e113-e123. doi: 10.1016/S2666-5247(21)00235-4. Epub 2021 Dec 6. Lancet Microbe. 2022. PMID: 35544042 Free PMC article.
Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination.
Pejoski D, de Rham C, Martinez-Murillo P, Santoro F, Auderset F, Medaglini D, Pozzi G, Vono M, Lambert PH, Huttner A, Haks MC, Ottenhoff THM, Villard J, Siegrist CA; VEBCON Consortium; VSV-EBOVAC Consortium; VSV-EBOPLUS Consortium. Pejoski D, et al. NPJ Vaccines. 2020 Apr 14;5(1):32. doi: 10.1038/s41541-020-0179-4. eCollection 2020. NPJ Vaccines. 2020. PMID: 32337075 Free PMC article.
Erratum: Author Correction: Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination.
Pejoski D, de Rham C, Martinez-Murillo P, Santoro F, Auderset F, Medaglini D, Pozzi G, Vono M, Lambert PH, Huttner A, Haks MC, Ottenhoff THM, Villard J, Siegrist CA; VEBCON Consortium; VSV-EBOVAC Consortium; VSV-EBOPLUS Consortium. Pejoski D, et al. NPJ Vaccines. 2020 Oct 6;5:93. doi: 10.1038/s41541-020-00244-w. eCollection 2020. NPJ Vaccines. 2020. PMID: 33083028 Free PMC article.
A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa.
Huttner A, Combescure C, Grillet S, Haks MC, Quinten E, Modoux C, Agnandji ST, Brosnahan J, Dayer JA, Harandi AM, Kaiser L, Medaglini D, Monath T; VEBCON and VSV-EBOVAC Consortia; Roux-Lombard P, Kremsner PG, Ottenhoff TH, Siegrist CA. Huttner A, et al. Sci Transl Med. 2017 Apr 12;9(385):eaaj1701. doi: 10.1126/scitranslmed.aaj1701. Sci Transl Med. 2017. PMID: 28404856 Free PMC article.
Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.
Huttner A, Agnandji ST, Combescure C, Fernandes JF, Bache EB, Kabwende L, Ndungu FM, Brosnahan J, Monath TP, Lemaître B, Grillet S, Botto M, Engler O, Portmann J, Siegrist D, Bejon P, Silvera P, Kremsner P, Siegrist CA; VEBCON; VSV-EBOVAC; VSV-EBOPLUS Consortia. Huttner A, et al. Lancet Infect Dis. 2018 Jul;18(7):738-748. doi: 10.1016/S1473-3099(18)30165-8. Epub 2018 Apr 5. Lancet Infect Dis. 2018. PMID: 29627147 Free PMC article.